Vienna / Valletta – QON, the Austria and Malta-based boutique private asset management and advisory firm, has been formally mandated to serve as a strategic consultant in the €4 billion sale of a leading European MedTech company. The transaction, currently one of the most significant healthcare acquisitions in the region, highlights QON’s growing reputation in high-level cross-border advisory within the medical technology and innovation sector.

The mandate underscores QON’s ability to navigate the intricacies of large-scale, international M&A transactions. The firm will act as an exclusive advisor to the selling consortium, which includes a group of institutional investors and founding stakeholders. The sale involves a globally recognized MedTech firm, known for its pioneering work in minimally invasive surgical systems, diagnostic platforms, and next-generation medical robotics.

“This transaction represents not only a milestone in the European MedTech space but also a strong affirmation of QON’s ability to advise at the highest level of industry consolidation,” said Michael de Bourbon, the CIO at QON. “We are honoured to support our clients in a deal that reflects the ongoing transformation of global healthcare systems and the accelerating convergence of technology and medicine.”

The unnamed acquirer is a strategic healthcare conglomerate with a global footprint, seeking to expand its presence in Europe and diversify its innovation pipeline. The acquisition is expected to create significant synergies, enhance R&D investment, and accelerate global access to advanced medical technologies.

QON’s mandate includes full-spectrum M&A advisory, including strategic positioning, valuation oversight, due diligence coordination, and stakeholder negotiations. The transaction is anticipated to close in Q3 2026, subject to regulatory approval and customary conditions.

With this mandate, QON further solidifies its standing as a trusted partner in complex cross-border transactions. Known for its discreet advisory model and highly curated client relationships, the firm has consistently delivered strategic outcomes for ultra-high-net-worth individuals, family offices, and institutional investors across Europe and the Middle East.

This latest engagement adds to QON’s growing portfolio of strategic mandates in the life sciences, technology, and industrial sectors. The firm continues to position itself at the intersection of capital, innovation, and long-term value creation – offering advisory services that go beyond transactions to serve as long-term strategic counsel.